Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Margherita RiminiShigeo ShimoseSara LonardiToshifumi TadaGianluca MasiHideki IwamotoEleonora LaiValentina BurgioAtsushi HiraokaToru IshikawaCaterina SoldàTomotake ShironoCaterina VivaldiKoichi TakaguchiNoritomo ShimadaGiorgio AstaraHironori KogaKazuhiro NousoKouji JokoTakuji TorimuraYoichi HiasaFrancesca SalaniMario ScartozziStefano CascinuAndrea Casadei-GardiniPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
SLenvatinib showed to better perform in a real-word setting compared to Sorafenib. More researches are needed to validate the predictor factors of response to Lenvatinib rather than Sorafenib.
Keyphrases